Panaccione R, Louis E, Colombel JF, D'Haens G, et al. Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies. J Crohns Colitis 2025;19:jjaf005.
PMID: 39804294